These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 20220045

  • 1. Effect of casopitant, a novel NK-1 receptor antagonist, on the pharmacokinetics and pharmacodynamics of steady-state warfarin.
    Kirby LC, Johnson BM, Adams LM, Eberwein DJ, Zhang K, Murray SC, Lates CD, Blum RA, Morris SR.
    J Clin Pharmacol; 2010 May; 50(5):566-75. PubMed ID: 20220045
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Ketoconazole and rifampin significantly affect the pharmacokinetics, but not the safety or QTc interval, of casopitant, a neurokinin-1 receptor antagonist.
    Johnson BM, Adams LM, Zhang K, Gainer SD, Kirby LC, Blum RA, Apseloff G, Morrison RA, Schutz RA, Lebowitz PF.
    J Clin Pharmacol; 2010 Aug; 50(8):951-9. PubMed ID: 20124517
    [Abstract] [Full Text] [Related]

  • 4. Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy.
    Arpornwirat W, Albert I, Hansen VL, Levin J, Bandekar RR, Grunberg SM.
    Cancer; 2009 Dec 15; 115(24):5807-16. PubMed ID: 19834961
    [Abstract] [Full Text] [Related]

  • 5. Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
    Herrstedt J, Apornwirat W, Shaharyar A, Aziz Z, Roila F, Van Belle S, Russo MW, Levin J, Ranganathan S, Guckert M, Grunberg SM.
    J Clin Oncol; 2009 Nov 10; 27(32):5363-9. PubMed ID: 19805683
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The effect of rofecoxib on the pharmacodynamics and pharmcokinetics of warfarin.
    Schwartz JI, Bugianesi KJ, Ebel DL, De Smet M, Haesen R, Larson PJ, Ko A, Verbesselt R, Hunt TL, Lins R, Lens S, Porras AG, Dieck J, Keymeulen B, Gertz BJ.
    Clin Pharmacol Ther; 2000 Dec 10; 68(6):626-36. PubMed ID: 11180023
    [Abstract] [Full Text] [Related]

  • 8. The effect of fimasartan, an angiotensin receptor type 1 blocker, on the pharmacokinetics and pharmacodynamics of warfarin in healthy Korean male volunteers: a one-sequence, two-period crossover clinical trial.
    Gu N, Kim BH, Lim KS, Kim SE, Nam WS, Yoon SH, Cho JY, Shin SG, Jang IJ, Yu KS.
    Clin Ther; 2012 Jul 10; 34(7):1592-600. PubMed ID: 22727611
    [Abstract] [Full Text] [Related]

  • 9. Influence of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the pharmacokinetics and pharmacodynamics of warfarin.
    Schwartz JI, Liu F, Stroh M, Gipson A, Johnson-Levonas AO, Lasseter KC, Lai E, Wagner JA.
    Am J Ther; 2009 Jul 10; 16(3):215-23. PubMed ID: 19454860
    [Abstract] [Full Text] [Related]

  • 10. Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin.
    Depré M, Van Hecken A, Oeyen M, De Lepeleire I, Laethem T, Rothenberg P, Petty KJ, Majumdar A, Crumley T, Panebianco D, Bergman A, de Hoon JN.
    Eur J Clin Pharmacol; 2005 Jul 10; 61(5-6):341-6. PubMed ID: 15983826
    [Abstract] [Full Text] [Related]

  • 11. Influence of taranabant, a cannabinoid-1 receptor inverse agonist, on pharmacokinetics and pharmacodynamics of warfarin.
    Schwartz JI, Dunbar S, Yuan J, Li S, Gipson A, Rosko K, Johnson-Levonas AO, Lasseter KC, Addy C, Stoch AS, Wagner JA.
    Adv Ther; 2008 Nov 10; 25(11):1175-90. PubMed ID: 18989636
    [Abstract] [Full Text] [Related]

  • 12. Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone.
    Johnson B, Adams L, Lu E, Zhang K, Lebowitz P, Lates C, Blum R.
    Support Care Cancer; 2009 Sep 10; 17(9):1177-85. PubMed ID: 19205755
    [Abstract] [Full Text] [Related]

  • 13. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.
    Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ.
    Br J Clin Pharmacol; 2004 May 10; 57(5):592-9. PubMed ID: 15089812
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Absence of a pharmacokinetic interaction between etanercept and warfarin.
    Zhou H, Patat A, Parks V, Buckwalter M, Metzger D, Korth-Bradley J.
    J Clin Pharmacol; 2004 May 10; 44(5):543-50. PubMed ID: 15102876
    [Abstract] [Full Text] [Related]

  • 16. Lack of pharmacokinetic and pharmacodynamic interactions between a smoking cessation therapy, varenicline, and warfarin: an in vivo and in vitro study.
    Burstein AH, Clark DJ, O'Gorman M, Willavize SA, Brayman TG, Grover GS, Walsky RL, Obach RS, Faessel HM.
    J Clin Pharmacol; 2007 Nov 10; 47(11):1421-9. PubMed ID: 17962429
    [Abstract] [Full Text] [Related]

  • 17. Effect of montelukast on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.
    Van Hecken A, Depré M, Verbesselt R, Wynants K, De Lepeleire I, Arnout J, Wong PH, Freeman A, Holland S, Gertz B, De Schepper PJ.
    J Clin Pharmacol; 1999 May 10; 39(5):495-500. PubMed ID: 10234597
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Phase II study to evaluate the safety and efficacy of the oral neurokinin-1 receptor antagonist casopitant (GW679769) administered with ondansetron for the prevention of postoperative and postdischarge nausea and vomiting in high-risk patients.
    Singla NK, Singla SK, Chung F, Kutsogiannis DJ, Blackburn L, Lane SR, Levin J, Johnson B, Pergolizzi JV.
    Anesthesiology; 2010 Jul 10; 113(1):74-82. PubMed ID: 20526194
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.